newsfilter
← Latest News
GlobeNewswire·

ObsEva Announces Third Quarter 2021 Financial Results and Business Update

-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Global Li